RxDoctor Payments Data

Mohsin Alhaddad, MD

Cardiovascular Disease · Jackson, TNNPI 1467624619

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,807 of the $13,867 with a category attached, or 70.7%. 46 manufacturers reported payments, led by Angiodynamics, Inc. at 31.4% of the total. Reporting peaked in 2021 at $4,444 and has fallen 59.2% since, to $1,812 in 2025.

$13,867in general payments, 2019–2025

Across 528 payments — averaging $26.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$4K
  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$856
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$778
  • Boehringer Ingelheim$680
  • Sirtex Medical Inc$617
  • plus $5K from 40 others
$1,794,802in research payments, 2019–2025

Across 511 payments — averaging $3512.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$1M
  • Janssen Research & Development, LLC$277K
  • Boehringer Ingelheim International GmbH$169K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$121K
  • Merck$102K
  • Bayer$39K
  • plus $41K from 6 others

What the payments were for

  • Food & beverage$9,80771%
  • Education$4,06029%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,867 in reported general payments places this provider in the 85th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,030,578
Medicare patients
1,273
Services billed
7,933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,286$965,107
EntrestoSacubitril/Valsartan454$406,665
FarxigaDapagliflozin Propanediol311$223,493
XareltoRivaroxaban271$183,281
AdempasRiociguat14$164,808
JardianceEmpagliflozin169$135,944
BrilintaTicagrelor182$116,508
Repatha SureclickEvolocumab113$77,507
Ranolazine ErRanolazine245$23,623
VascepaIcosapent Ethyl40$20,115
VerquvoVericiguat15$18,242
Sildenafil Citrate31$11,226
OzempicSemaglutide12$10,828
Atorvastatin Calcium908$10,383
MultaqDronedarone Hcl11$9,776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$517$965,1071,286 claims
NovartisEntresto$1,110$406,665454 claims
AstraZenecaFarxiga, Brilinta$392$340,001493 claims
Johnson & JohnsonXarelto$497$183,281271 claims
BayerAdempas$12$164,80814 claims
Boehringer IngelheimJardiance$680$135,944169 claims
MerckVerquvo$464$18,24215 claims
Novo NordiskOzempic$98$10,82812 claims
Sanofi-aventis U.S. LLCMultaq$119$9,77611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Jackson

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →